亚太地区急性髓性白血病治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

亚太地区急性髓性白血病治疗市场按治疗(化疗、靶向治疗、干细胞移植、其他治疗)和地理划分

市场快照

CAGR
Study Period: 2018 - 2026
Base Year: 2021
CAGR: 8.15 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

亚洲地区的 AML 病例呈上升趋势,这增加了针对白血病患者新疗法的临床试验数量。根据 Astellas Pharma Inc 2018 年的一份报告,在日本,每年约有 4,500 名患者被诊断出患有 AML。此外,该调查还报告称,老年人群中 AML 的患病率更高。随着老年人口的百分比增加,这种疾病可能会给整个人口带来经济负担。

根据 Elton B. Stephens Co. (EBSCO) 2017 年的报告,低收入亚太国家和高收入亚太国家的 AML 患病率(5 年期)分别为每 100,000 人中有 4 人和每 100,000 人中有 7 人, 分别。亚太地区的国家不仅在经济上处于发展中,而且其人口也在以每年显着的速度增长。因此,随着这些国家人口的增加,AML 的发病风险也很高。

因此,由于亚太地区 AML 患病率的增加,预计该市场将在预测期内增长。

报告范围

根据报告的范围,急性髓细胞白血病也称为急性髓细胞白血病、急性髓细胞白血病、急性粒细胞白血病或急性非淋巴细胞白血病。在急性髓性白血病中,异常白细胞快速产生,这些白细胞聚集在骨髓中并干扰正常血细胞的产生。

By Therapy
Chemotherapy
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Other Chemotherapies
Targeted Therapy
Stem Cell Transplant
Other Therapies
Geography
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific

Report scope can be customized per your requirements. Click here.

主要市场趋势

因此,预计化疗在预测期内将占据最大的市场份额

化疗是大多数急性髓性白血病 (AML) 患者的主要治疗方法。诱导是治疗的第一阶段。它是短暂而密集的,通常持续大约一周。目标是清除血液中的白血病细胞(原始细胞)并将骨髓中原始细胞的数量减少到正常。巩固是在患者从诱导中恢复后进行的化疗。它旨在杀死仍然存在但看不到的少量白血病细胞(因为它们太少了)。为了巩固,化疗是按周期进行的,每个治疗期之后是休息期,让身体有时间恢复。第三阶段称为维持(或巩固后)涉及在巩固完成后数月或数年给予低剂量化疗。

道诺霉素、伊达比星和米托蒽醌等药物一直占据市场主导地位,预计新的研究发现将进一步帮助该领域的增长。此外,白血病的患病率正在增加,而 AML 是白血病中最常见的死亡原因之一。因此,预计亚洲 AML 的发病率也会增加。这将增加 AML 治疗的需求,有助于市场增长。

graphAMLAsia-2.png

竞争格局

亚太地区急性髓性白血病治疗市场竞争适度,主要由全球参与者组成。该市场的一些主要参与者包括诺华公司、辉瑞公司、梯瓦制药、艾伯维公司等。随着制药公司越来越关注为癌症提供更好的治疗方法,相信在不久的将来会有更多的公司进入市场。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia

      2. 4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development

    3. 4.3 Market Restraints

      1. 4.3.1 Complications Related to Chemotherapy

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Therapy

      1. 5.1.1 Chemotherapy

        1. 5.1.1.1 Anthracycline Drugs

        2. 5.1.1.2 Alkylating Agents

        3. 5.1.1.3 Anti-metabolites

        4. 5.1.1.4 Other Chemotherapies

      2. 5.1.2 Targeted Therapy

      3. 5.1.3 Stem Cell Transplant

      4. 5.1.4 Other Therapies

    2. 5.2 Geography

      1. 5.2.1 Asia Pacific

        1. 5.2.1.1 China

        2. 5.2.1.2 Japan

        3. 5.2.1.3 India

        4. 5.2.1.4 Australia

        5. 5.2.1.5 South Korea

        6. 5.2.1.6 Rest of Asia-Pacific

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Astellas Pharma Inc.

      2. 6.1.2 AbbVie Inc.

      3. 6.1.3 Celgene Corporation

      4. 6.1.4 Daiichi Sankyo Company Limited

      5. 6.1.5 Novartis AG

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 Teva Pharmaceutical Industries Ltd

      8. 6.1.8 Mylan NV

      9. 6.1.9 Sun Pharmaceutical Industries Ltd

      10. 6.1.10 Fresenius SE & Co. KGaA

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asia-Pacific Acute Myeloid Leukemia Treatment Market | Growth, Trends, and Forecast (2020 - 2025) market is studied from 2018 - 2026.

The Asia-Pacific Acute Myeloid Leukemia Treatment Market | Growth, Trends, and Forecast (2020 - 2025) is growing at a CAGR of 8.15% over the next 5 years.

AbbVie Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical, Sun Pharmaceutical Industries Ltd are the major companies operating in Asia-Pacific Acute Myeloid Leukemia Treatment Market | Growth, Trends, and Forecast (2020 - 2025).

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!